The headline number from Eli Lilly's TRIUMPH-1 Phase 3 trial is 70.3 pounds — an average of 28.3% body weight reduction at 80 weeks on the 12 mg dose of retatrutide.

That number is real, it is significant, and it is getting all the attention.

But the number worth studying — particularly for understanding the full dose-response picture — is in the 4 mg column.

And almost nobody is talking about it.

What TRIUMPH-1 Actually Showed

TRIUMPH-1 is the pivotal Phase 3 obesity trial for retatrutide, an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. Eli Lilly announced topline results in May 2026. Lead investigator: Dr. Ania Jastreboff, MD PhD, Professor of Medicine and Pediatrics (Endocrinology), Yale School of Medicine, Director of the Yale Obesity Research Center.

All three doses met primary and key secondary endpoints. Here is the full dose-response picture at 80 weeks, directly from the Lilly press release:

| Dose | Avg Weight Loss | Avg Lbs Lost | ≥25% Reduction | ≥30% Reduction | |------|----------------|-------------|----------------|----------------| | Placebo | -2.2% | -5.5 lbs | 2.2% | 0.5% | | 4 mg | -19.0% | -47.2 lbs | 27.8% | 15.3% | | 9 mg | -25.9% | -64.4 lbs | 52.9% | 37.9% | | 12 mg | -28.3% | -70.3 lbs | 62.5% | 45.3% |

The extension data (104 weeks, BMI ≥35 subgroup) showed continued weight loss at all doses — including 30.3% at 12 mg for those who kept going past year one.

The 4 mg Column

Here is what stands out about the lowest dose arm.

4 mg requires only a single escalation step — participants started at 2 mg and moved to 4 mg. That is it. No further titration required.

4 mg produced 19% average weight loss at 80 weeks. For loose context, the STEP 1 trial of semaglutide reported approximately 14.9% at 68 weeks, and the SURMOUNT-1 trial of tirzepatide reported approximately 22.5% at 72 weeks. These were separate trials with different designs, populations, and durations — direct comparison is imprecise — but they place retatrutide's 4 mg result in the same general range as other leading agents in the class.

4 mg had a discontinuation rate comparable to — and marginally below — placebo.

This is the finding that deserves more attention. In obesity trials, placebo arms typically have very low dropout rates — participants are receiving a saline injection, so side effects are minimal. Active drug arms almost always have higher discontinuation from adverse events. That is the expected curve.

In TRIUMPH-1, the 4 mg arm held to it. Discontinuation due to adverse events was 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% for placebo. The official Lilly press release noted the 4 mg dose showed "a lower observed discontinuation rate due to adverse events vs. placebo" — a marginal difference, but a genuinely notable tolerability signal for an active drug producing 19% weight loss: at this dose, retatrutide was about as well-tolerated as a saline injection.

The Dose-Tolerance Tradeoff

The full dose-response picture in TRIUMPH-1 is a textbook illustration of how efficacy and tolerability trade off as dose increases. The data suggest a meaningful inflection point around 4 mg.

In TRIUMPH-1, tripling the dose from 4 mg to 12 mg added approximately 9 percentage points of weight loss (19% to 28.3%) among trial participants. The 12 mg dose also produced a higher incidence of GI side effects and dysesthesia (tingling or altered skin sensation, a known effect at higher glucagon receptor activation levels) compared to the lower doses — with discontinuation rates rising from 4.1% at 4 mg (below the 4.9% placebo rate) to 11.3% at 12 mg.

The trial data present a clear dose-response tradeoff: more weight loss at higher doses, with a corresponding increase in side-effect burden and discontinuation. Whether that tradeoff is worthwhile is an individual clinical question that depends on a patient's specific goals, baseline, and health context — exactly the kind of question a knowledgeable prescribing physician is positioned to help answer.

What Retatrutide Is and How It Differs

Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist — the first of its class to reach Phase 3. The addition of glucagon receptor activity is what distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).

Glucagon receptor activation influences energy expenditure and fat oxidation directly — mechanisms that operate somewhat independently of the appetite suppression pathways that GLP-1 primarily targets. This is the mechanistic rationale for why retatrutide's efficacy data has exceeded prior-generation compounds at comparable timepoints.

Retatrutide is still investigational — it is not FDA-approved as of this writing. Lilly is expected to submit for approval based on the TRIUMPH program data.

What the Cardiovascular Data Shows

Beyond weight loss, TRIUMPH-1 reported significant improvements from baseline across several cardiovascular risk factors on all doses:

Waist circumference: -16.3 cm (4 mg) to -24.1 cm (12 mg)
Non-HDL cholesterol: improved across all arms
Triglycerides: improved across all arms
Systolic blood pressure: improved across all arms
High-sensitivity C-reactive protein (hsCRP): improved across all arms

The cardiometabolic signal here is notable. These improvements were observed across all three dose arms in the trial.

Where Retatrutide Fits in the Landscape

The GLP-1 medication landscape is shifting faster than most patients and providers can track. Here is where retatrutide sits relative to approved options as of May 2026:

| Compound | Mechanism | Avg Weight Loss | Status | |----------|-----------|----------------|--------| | Semaglutide (Wegovy) | GLP-1 | ~14.9% at 68 weeks | FDA Approved | | Tirzepatide (Zepbound) | GLP-1 + GIP | ~22.5% at 72 weeks | FDA Approved | | Orforglipron (Foundayo) | Oral GLP-1 | ~12.4% at 36 weeks (ATTAIN-1) | FDA Approved April 1, 2026 | | Retatrutide | GLP-1 + GIP + Glucagon | 19-28.3% at 80 weeks | Investigational |

These figures come from separate trials with different designs and populations; direct cross-trial comparison is imprecise. They are included here for general context about where TRIUMPH-1 results sit within the broader landscape of published Phase 3 data in this class.

Why This Matters Now

Retatrutide is not yet available by prescription. Understanding the TRIUMPH-1 data now — before it reaches the prescription market — is how you walk into a future provider conversation informed. The trial showed meaningful results across all three doses, with distinct efficacy and tolerability profiles at each level. How any of that applies to an individual's situation is a conversation for a qualified prescribing physician.

PeptidesGPT's AI Coach has been updated with the TRIUMPH-1 data. If you want to understand how retatrutide compares to other compounds in the class, ask the Coach.

→ Ask the Coach at PeptidesGPT.com

Sources:

Eli Lilly official press release: "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" — investor.lilly.com, May 2026 (TRIUMPH-1 topline results)
Lead investigator: Dr. Ania Jastreboff, MD PhD — Yale School of Medicine
Comparative data: STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide) — previously published Phase 3 trial results

PeptidesGPT is an educational platform. The content above discusses clinical trial data for informational purposes only. It is not medical advice and is not a substitute for consultation with a licensed healthcare provider. Retatrutide is investigational and not FDA-approved as of this writing. Always consult your physician before making decisions about your medications or health protocol.